Identification and structure-activity relationship of 2-morpholino 6-(3-hydroxyphenyl) pyrimidines, a class of potent and selective PI3 kinase inhibitors

Bioorganic and Medicinal Chemistry Letters

Volumn 20, Issue 23, 2010, Pages 6895-6898

  Pecchi, Sabina ^a   Renhowe, Paul A ^a   Taylor, Clarke ^c   Kaufman, Susan ^a   Merritt, Hanne ^a   Wiesmann, Marion ^b   Shoemaker, Kevin R ^a   Knapp, Mark S ^a   Ornelas, Elizabeth ^a   Hendrickson, Thomas F ^d   Fantl, Wendy ^e   Voliva, Charles F ^a  

^a NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

^b NOVARTIS PHARMA AG   (Switzerland)

^c Lycera Corporation   (United States)

^d Supergen Inc   (United States)

^e Nodality Inc   (United States)

Author keywords

2 Morpholino pyrimidines; Cancer treatment; Phosphoinositol; PI3 Kinase; PI3 Kinase inhibitors

Indexed keywords

2 MORPHOLINO 6 (3 HYDROXYPHENYL)PYRIMIDINE; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PROTEIN KINASE B; PYRIMIDINE DERIVATIVE; UNCLASSIFIED DRUG;

ARTICLE; CANCER CELL; CONTROLLED STUDY; DRUG POTENCY; DRUG SELECTIVITY; DRUG SYNTHESIS; HUMAN; HUMAN CELL; IC 50; MOLECULAR DOCKING; STRUCTURE ACTIVITY RELATION;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL PROLIFERATION; HUMANS; MORPHOLINES; PHOSPHATIDYLINOSITOL 3-KINASES; PHOSPHORYLATION; PROTEIN KINASE INHIBITORS; PYRIMIDINES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 78149283201     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2010.10.021     Document Type: Article

References (20)

1. B. Vanhaesebroeck, S.J. Leevers, K. Ahmadi, J. Timms, R. Katso, P.C. Driscoll, R. Woscholski, P.J. Parker, and M.D. Waterfield Annu. Rev. Biochem. 70 2001 535
2. R. Katso, K. Okkenhaug, and K. Ahmadi Annu. Rev. Cell Dev. Biol. 17 2001 615
3. M.P. Wymann, M. Zvelebil, and M. Laffargue Trends Pharmacol. Sci. 24 2003 366
4. A.D. Kohn, F. Takeuchi, and R.A. Roth J. Biol. Chem. 271 1996 21920
5. M. Andjelkovic, D.R. Alessi, and R. Meier J. Biol. Chem. 272 1997 31515
6. P. Liu, H. Cheng, T.M. Roberts, and J.J. Zhao Nat. Rev. Drug Disc. 8 2009 627
7. I.U. Ali, L.M. Schriml, and M. Dean J. Natl. Cancer Inst. 91 1999 1922
8. D.A. Cross, D.R. Alessi, and P. Cohen Nature 378 1995 785
9. Y. Samuels, Z. Wang, and A. Bardelli Science 304 2004 554
10. D. Kong, and T. Yamori Cancer Sci. 99 2008 1734
11. J.M. Nuss, A.L. Tsuhako, and N.K. Anand J.E. Macor, Annu. Rep. Med. Chem. Vol. 44 2009 Academic Press Oxford 339 351
12. P. Workman, P.A. Clarke, F.I. Raynaud, and R.L.M. Van Montfort Cancer Res. 70 2010 2146
13. M.F. Gordeev, D.V. Patel, J. Wu, and E.M. Gordon Tetrahedron Lett. 37 1996 4643
14. Kim, J.-W. PCT Int. Appl. WO04048369, 2004.
15. C. Gueremy, F. Audiau, C. Renault, J. Benavides, A. Uzan, and G. Le Fur J. Med. Chem. 29 1986 1394
16. 2O, 300 MHz): δ ppm 8.09 (s, 1H), 8.03 (br s, 1H), 7.61 (d, 1H, J = 7.8 Hz), 7.55 (br m, 1H), 7.38 (app. t, 1H, J = 7.8 Hz), 7.17 (br d, 1H, J = 7.8 Hz), 7.10 (br s, 1H), 7.06 (d, 1H, J = 8.7 Hz), 6.42 (br s, 1H), 3.75 (br s, 8H); LCMS m/z (%): 389.2 (M+H).
17. The model for compound in p110α was built in Maestro 8.0.308 after merging the compound 25 coordinates from a Novartis structure of the compound bound to PI3K p110γ (PDB accession code: 3P2B) with the aligned coordinates of the public domain p110α apo-structure (PDB deposition code: 2RD0). All key protein-compound interactions are retained between the p110γ structure and the p110α model and no new interactions are expected with the other PI3K Class I isoforms.
18. 50 is 0.55 μM for 25.
19. E.H. Walker, M.E. Pacold, and O. Perisic Mol. Cell 6 2000 909
20. Z.A. Knight, G.G. Chiang, P.G. Alaimo, D.M. Kenski, C.B. Ho, K. Coan, R.T. Abraham, and K.M. Shokat Bioorg. Med. Chem. 12 2004 4749